BREAKING NEWS

Biogen submits US marketing application for Alzheimer's disease drug

Biogen Inc said on Wednesday that it submitted the marketing application for its experimental Alzheimer's disease therapy, aducanumab, to the U.S. Food and Drug Administration.
Subscribe for our daily newsletter
Subscribe for our daily newsletter

By subscribing I accept the terms of use